Table 1. Association of AD with LCR1 CNV.
| LCR1 CNV | CR1 isoform |
Patients |
Controls |
P | P-adj | OR | 95% CI | ||
|---|---|---|---|---|---|---|---|---|---|
| n | n | % | n | % | |||||
| Belgian sample | |||||||||
| 2 | F/F | 595 | 62.3 | 525 | 68.9 | 0.013 | 0.083 | ref. | |
| 3 | F/S | 312 | 32.7 | 201 | 26.4 | 0.003 | 0.028 | 1.32 | 1.03–1.69 |
| 4 | S/S or F/D | 48 | 5.0 | 36 | 4.7 | 0.574 | 0.583 | 1.16 | 0.69–1.94 |
| French sample | |||||||||
| 2 | F/F | 793 | 64.9 | 406 | 70.5 | 0.084 | 0.049 | ref. | |
| 3 | F/S | 354 | 30.0 | 142 | 24.7 | 0.032 | 0.039 | 1.33 | 1.02–1.74 |
| 4 | S/S or F/D | 74 | 6.1 | 28 | 4.9 | 0.500 | 0.456 | 1.44 | 0.87–2.40 |
Abbreviations: AD, Alzheimer disease; CI, confidence interval; CNV, copy number variation; CR1, complement receptor 1 gene; LCR, low-copy repeats; OR, odds ratio.
Note: significant associations (P<0.05) are indicated in bold; P-adj represent P-values adjusted for age, gender and APOE ɛ4 genotype.